Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 13.32M P/E - EPS this Y 39.70% Ern Qtrly Grth -
Income -14.29M Forward P/E -1.96 EPS next Y 59.70% 50D Avg Chg 8.00%
Sales 583.23k PEG - EPS past 5Y - 200D Avg Chg -45.00%
Dividend N/A Price/Book 0.50 EPS next 5Y - 52W High Chg -85.00%
Recommedations 1.70 Quick Ratio 4.93 Shares Outstanding 5.43M 52W Low Chg 653.00%
Insider Own 11.67% ROA -36.63% Shares Float 4.19M Beta -
Inst Own 17.70% ROE -63.19% Shares Shorted/Prior 96.18K/117.11K Price 3.57
Gross Margin - Profit Margin - Avg. Volume 46,459 Target Price 15.67
Oper. Margin -26,109.62% Earnings Date May 13 Volume 64,778 Change 15.16%
About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Aprea Therapeutics, Inc. News
04/10/24 Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
03/26/24 Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
03/11/24 Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
03/11/24 Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
03/05/24 Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
02/06/24 Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
01/30/24 Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
01/10/24 Will Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely?
01/04/24 Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
11/09/23 Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
10/24/23 Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
10/16/23 Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
09/19/23 Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
09/11/23 Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors
09/06/23 Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08/24/23 Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
08/10/23 Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
06/14/23 Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
05/30/23 Aprea Therapeutics to Present at BIO International Convention
05/15/23 Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
APRE Chatroom

User Image breakman1010 Posted - 3 days ago

$JAGX $apre

User Image Deepsyd Posted - 1 week ago

$APRE Just 30 days left till CVR expiry if you feel like selling anything Gilad….

User Image Stock_Titan Posted - 2 weeks ago

$APRE Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024 https://www.stocktitan.net/news/APRE/aprea-therapeutics-announces-presentations-on-its-next-generation-88p8ok3dfvz1.html

User Image STONKSROCKET Posted - 2 weeks ago

$APRE do we have any possible catalysts coming up? Any information would be appreciated.

User Image OpenOutcrier Posted - 3 weeks ago

$APRE (-6.5% pre) Aprea Therapeutics (APRE) Announces 4.39M Share Offering by Selling Stockholders - SI https://ooc.bz/l/29431

User Image BornKing Posted - 3 weeks ago

$APRE same story, they hid from shareholders under the umbrella on a terrible acquisition,R/S/offering. They fuqn broke

User Image BornKing Posted - 3 weeks ago

$APRE told yall they hustled us pre reverse split & shitty offering. Put hands & feet on management on sight🧐☕️

User Image DonCorleone77 Posted - 3 weeks ago

$APRE Aprea Therapeutics files to sell 4.39M shares of common stock for holders

User Image BornKing Posted - 3 weeks ago

$APRE still bih

User Image Papilove Posted - 3 weeks ago

$APRE @CharlesV @DTPantera King Charles I hope all is well with you and your family and you had a blessed resurrection Sunday yesterday. I need your help please with some information. In one or more of your previous posts, you mentioned that there was an FDA meeting with APRE executives around Q1 of 2022. You said some guy who runs a fund got inside information about this meeting and started shorting the stock. Also he was helped by Stock Authority. I am suing both of these people and anyone else involved on charges of conspiracy to commit securities fraud. This can bleed over to a lawsuit against APRE for non-disclosure of material information that resulted in huge investment losses. I need the names and all information you can help with. I found a second law firm to handle this case, whereas I have Cohen Milstein for the class-action involving the CVR. Thanks very much my friend.

User Image BornKing Posted - 03/28/24

$APRE $46 a share or this 💩 is forever trash scam

User Image Fullratio Posted - 03/27/24

$APRE current ratio has decreased by 45% YoY and by 16% from the previous quarter: https://fullratio.com/stocks/nasdaq-apre/aprea-therapeutics

User Image DonCorleone77 Posted - 03/26/24

$APRE Aprea Therapeutics sees cash runway into 3Q25 As of December 31, 2023, the Company reported cash and cash equivalents of $21.6 million compared to $28.8 million as of December 31, 2022. The Company believes its cash and cash equivalents as of December 31, 2023, combined with the upfront gross proceeds of approximately $16.0 million received from the Company's private placement of common stock and warrants in March 2024, before deducting placement agent fees and offering costs of approximately $1.4 million, will be sufficient to meet its currently projected operating expenses and capital expenditure requirements into the third quarter of 2025.

User Image DonCorleone77 Posted - 03/26/24

$APRE 2 of 2 - Aprea Therapeutics reports Q4 EPS (92c), consensus (77c) ....Based on the unique characteristics of APR-1051 we believe it will be best in class. The closing of our recent private placement financing provides us with the capital to fund both of these lead programs through meaningful clinical milestones. I would like to thank our dedicated team, our academic collaborators, as well as existing and new investors who have supported our recent advancements. Our mission is to be a global leader in synthetic lethality and we see a great opportunity to help cancer patients in need and create value for our shareholders."

User Image DonCorleone77 Posted - 03/26/24

$APRE 1 of 2 - Aprea Therapeutics reports Q4 EPS (92c), consensus (77c) Reports Q4 revenue $14,075. "Aprea had a very productive 2023 with significant progress across our diversified pipeline of synthetic lethality-based cancer therapeutics. We are pleased to continue this positive momentum in 2024 and focus on the execution on our programs towards successfully delivering potentially safer and more effective therapies for cancer patients," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "We continue to enroll and treat patients in the ongoing Phase 1/2a study of our novel macrocyclic ATR inhibitor, ATRN-119. ATRN-119 appears to be well tolerated with a manageable toxicity profile. Dose escalation will proceed throughout 2024 with potential for human efficacy data in the second half of the year. We are preparing to enter the clinic with our next generation inhibitor of WEE1 kinase, APR-1051, having received clearance from the FDA on our IND....

User Image Stock_Titan Posted - 03/26/24

$APRE Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update https://www.stocktitan.net/news/APRE/aprea-therapeutics-reports-fourth-quarter-and-full-year-2023-qp8d0w56vbqv.html

User Image DTPantera Posted - 1 month ago

$APRE an epic POS

User Image stockobserver Posted - 1 month ago

$APRE Still cheap

User Image dcast Posted - 1 month ago

$APRE marching back up. ready for the 7's

User Image stockobserver Posted - 1 month ago

$APRE Told you last week So undervalued. Now it’s hard to get shares.

User Image RollingDollar Posted - 1 month ago

$APRE

User Image RollingDollar Posted - 1 month ago

$APRE

User Image RollingDollar Posted - 1 month ago

$APRE

User Image _StockTrader Posted - 1 month ago

Real-Time Stock Data $APRE Price: 6.55 Volume: 21691 Market Cap: 21897260 PE Ratio: -2.616116 Powered by: AITX

User Image stockobserver Posted - 1 month ago

$APRE Screaming buy!

User Image stockobserver Posted - 1 month ago

$APRE Like a thief in the night Adding all week Look at the The terms of the finance and we are under 6???? Thanks

User Image insiderbuyingselling Posted - 1 month ago

$APRE new insider buying: 6860 shares. http://insiderbuyingselling.com/?t=APRE

User Image CEOBuysDisclosures Posted - 1 month ago

$APRE CEO purchased 2,000 shares at $7.29 for a total of $14,580. Gilad Oren now owns 324,770 shares. https://ceo-buys.com

User Image dcast Posted - 1 month ago

$APRE what is going on here? pops up to $12 after solid uptrend and now back to the $5s?

User Image ryszardm15 Posted - 1 month ago

$APRE Great news and low float. Just bought more shares.

Analyst Ratings
Wedbush Outperform Mar 27, 24
HC Wainwright & Co. Buy Mar 26, 24
HC Wainwright & Co. Buy Nov 1, 23
HC Wainwright & Co. Buy Sep 13, 23
HC Wainwright & Co. Buy Aug 10, 23
HC Wainwright & Co. Buy May 16, 23
Maxim Group Buy Mar 10, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Attar Eyal C. SVP, Chief Medical O.. SVP, Chief Medical Officer Feb 28 Sell 1.73 36,000 62,280 47,000 03/01/22
Korbel Gregory Alan SVP, Chief Business.. SVP, Chief Business Officer Nov 01 Option 0.92 27,500 25,300 44,667 11/03/21
Korbel Gregory Alan SVP, Chief Business.. SVP, Chief Business Officer Nov 01 Sell 5 27,500 137,500 17,167 11/03/21